Genetic Heart Disease Cure Advances UK, US, Singapore Teams

Recent advances in heart health treatments and innovation offer new hope for patients with various cardiac conditions. The CureHeart Project is pioneering genetic therapies to potentially cure inherited heart muscle diseases by editing faulty genes, showing promise in animal trials but not yet in humans. Meanwhile, the Sapien M-3 valve device developed in Tulsa provides a minimally invasive treatment for mitral valve disease, especially benefiting patients ineligible for traditional surgery, and has gained approval for use in Europe. On a broader scale, the Australian Heart Foundation has funded diverse community projects aimed at increasing physical activity to reduce heart disease, emphasizing inclusivity and adaptability to different needs. Additionally, Sutter Health's virtual pharmacy program demonstrates how pharmacists can significantly improve care for heart failure patients through guideline-based virtual management, reducing hospitalizations and improving outcomes. These developments collectively mark significant progress in both treatment and prevention of heart disease worldwide.